Previous 10 | Next 10 |
RICHLAND, Wash., April 29, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the third quarter fiscal 2022 ended March 31,...
RICHLAND, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy, today announced that Chief Executive Officer Lori Woods will participate in a virtual fireside chat at the Oppenheimer 32 nd A...
RICHLAND, Wash., March 02, 2022 (GLOBE NEWSWIRE) -- Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 b...
Isoray, Inc. (ISR) Q2 2022 Earnings Conference Call Feb 08, 2022, 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mike Ott - Oppenheimer Tim Chiang - Northland Capital Kyle Krueger ...
IsoRay press release (NYSE:ISR): Q2 GAAP EPS of -$0.01 in-line. Revenue of $2.82M (+19.5% Y/Y) beats by $0.02M. Shares -0.39%. Gross profit as a percentage of revenues was 43.3% for the three months ended December 31, 2021 versus 49.5% in the prior year comparable period. Cash, cash equ...
Revenue Increased 19% Year-Over-Year Prostate Brachytherapy Revenue Increased 13% Year-Over-Year RICHLAND, Wash., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its financia...
IsoRay (NYSE:ISR) is scheduled to announce Q2 earnings results on Tuesday, February 8th, after market close. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $2.8M For further details see: IsoRay Q2 2022 Earnings Preview
RICHLAND, Wash., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal 2022 ended December ...
Isoray, Inc. (ISR) Q1 2022 Earnings Conference Call November 10, 2021 04:30 p.m. ET Company Representatives Lori Woods - Chief Executive Officer Jonathan Hunt - Chief Financial Officer Mark Levin - Investor Relations Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mi...
IsoRay (NYSE:ISR): FQ1 GAAP EPS of -$0.02 misses by $0.01. Revenue of $2.56M (+7.6% Y/Y) beats by $0.06M. Press Release Isoray CEO Lori Woods said, “We are encouraged by the prospects for our core prostate brachytherapy business which grew year over year again this quarter. A...
News, Short Squeeze, Breakout and More Instantly...
IsoRay Inc. Company Name:
ISR Stock Symbol:
NYSE Market:
RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed b...
C omp any’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced N ew ticker symbol to be NYSE American: CATX RICHLAND,...
The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful complet...